Endocannabinoids control platelet activation and limit aggregate formation under flow

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  De Angelis, Valentina ^a   Koekman, Arnold C ^a   Weeterings, Cees ^a   Roest, Mark ^a   De Groot, Philip G ^a   Herczenik, Eszter ^a   Maas, Coen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ALPHA GRANULE; ANANDAMIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN VI; MEMBRANE PROTEIN; PADGEM PROTEIN; PROTEIN KINASE SYK; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOXANE A2; UNCLASSIFIED DRUG; AMIDE; ARACHIDONIC ACID DERIVATIVE; BETA3 INTEGRIN; CALCIUM; CANNABINOID 2 RECEPTOR; CANNABIS; COLLAGEN; DRONABINOL; ENDOCANNABINOID; GLYCOPROTEIN IIB; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ARTICLE; CALCIUM MOBILIZATION; CELL INTERACTION; CELL SPREADING; CONTROLLED STUDY; DENSITOMETRY; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; PLATELET REACTIVITY; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; WESTERN BLOTTING; AGONISTS; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ARACHIDONIC ACIDS; BLOOD PLATELETS; CALCIUM; CANNABIS; COLLAGEN; DRONABINOL; ENDOCANNABINOIDS; FIBRINOGEN; HUMANS; INTEGRIN BETA3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEIN IIB; POLYUNSATURATED ALKAMIDES; PROTEIN-TYROSINE KINASES; RECEPTOR, CANNABINOID, CB2; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84907495402     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108282     Document Type: Article

References (28)

1. Korporaal SJA, Van Eck M, Adelmeijer J, Ijsseldijk M, Out R, et al. (2007) Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler. Thromb. Vasc. Biol. 27: 2476-2483. doi:10.1161/ATVBAHA.107.150698
2. Natarajan A, Zaman AG, Marshall SM (2008) Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 5: 138-144. doi:10.3132/ dvdr.2008.023
3. Catani MV, Gasperi V, Catanzaro G, Baldassarri S, Bertoni A, et al. (2010) Human platelets express authentic CB and CB receptors. Curr Neurovasc Res 7: 311-318
4. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34: 605-613
5. Klein TW, Newton C, Larsen K, Lu L, Perkins I, et al. (2003) The cannabinoid system and immune modulation. J. Leukoc. Biol. 74: 486-496. doi:10.1189/ jlb.0303101
6. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332. doi:10.1126/science.1115740
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949
8. De Laurentiis A, Fernández Solari J, Mohn C, Zorrilla Zubilete M, Rettori V (2010) Endocannabinoid system participates in neuroendocrine control of homeostasis. Neuroimmunomodulation 17: 153-156. doi:10.1159/000258711
9. Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. U.S.A. 96: 12198-12203
10. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2: 358-363. doi:10.1038/7268
11. Wagner JA, Varga K, Kunos G (1998) Cardiovascular actions of cannabinoids and their generation during shock. J. Mol. Med. 76: 824-836
12. Valk P, Verbakel S, Vankan Y, Hol S, Mancham S, et al. (1997) Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood 90: 1448-1457
13. Jiang S, Fu Y, Avraham HK (2011) Regulation of hematopoietic stem cell trafficking and mobilization by the endocannabinoid system. Transfusion 51 Suppl 4: 65S-71S. doi:10.1111/j.1537-2995.2011.03368.x
14. Maccarrone M, Bari M, Menichelli A, Del Principe D, Agrò AF (1999) Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett. 447: 277-282
15. Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA (2004) The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth. Analg. 99: 1127-30, table of contents. doi:10.1213/01.ANE.0000131505.03006.74
16. Levy R, Schurr A, Nathan I, Dvilanski A, Livne A (1976) Impairment of ADPinduced platelet aggregation by hashish components. Thromb. Haemost. 36: 634-640
17. Formukong EA, Evans AT, Evans FJ (1989) The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J. Pharm. Pharmacol. 41: 705-709
18. Catani MV, Gasperi V, Evangelista D, Finazzi Agrò A, Avigliano L, et al. (2010) Anandamide extends platelets survival through CB(1)-dependent Akt signaling. Cell. Mol. Life Sci. 67: 601-610. doi:10.1007/s00018-009-0198-9
19. Buchan BJ, L Dennis M, Tims FM, Diamond GS (2002) Cannabis use: consistency and validity of self-report, on-site urine testing and laboratory testing. Addiction 97 Suppl 1: 98-108
20. Sixma JJ, de Groot PG, van Zanten H, IJsseldijk M (1998) A new perfusion chamber to detect platelet adhesion using a small volume of blood. Thromb. Res. 92: S43-6
21. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, et al. (1995) Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J. Am. Coll. Cardiol. 26: 1665-1671. doi:10.1016/0735-1097(95)00391-6
22. Klinkhardt U, Kirchmaier CM, Westrup D, Breddin HK, Mahnel R, et al. (2000) Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters. Thromb. Res. 97: 201-207
23. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, et al. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98: 9371-9376. doi:10.1073/pnas.161191698
24. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9: 76-81. doi:10.1038/nm803
25. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3: 771-784. doi:10.1038/ nrd1495
26. Habayeb OMH, Taylor AH, Evans MD, Cooke MS, Taylor DJ, et al. (2004) Plasma levels of the endocannabinoid anandamide in women-a potential role in pregnancy maintenance and labor? J. Clin. Endocrinol. Metab. 89: 5482-5487. doi:10.1210/jc.2004-0681
27. Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem. Biodivers. 4: 1770-1804. doi:10.1002/cbdv.200790152
28. Jackson AR, Nagarkatti P, Nagarkatti M (2014) Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. PLoS ONE 9: e93954. doi:10.1371/journal.pone.0093954